Romiplostim to boost platelets after a stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called romiplostim to help your body make platelets faster after a stem cell transplant. Platelets help your blood clot, and getting them back sooner can reduce bleeding risks and speed recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a blood cancer (like leukemia or lymphoma) and are having or have had a stem cell transplant from a donor.
- You should be in good overall health, with your heart, lungs, liver, and kidneys working well enough.
- You must not have taken romiplostim, eltrombopag, or similar platelet-boosting drugs in the last month.
- You should not have had a recent blood clot, heart attack, or stroke (some exceptions may apply).
- If you could become pregnant, you must use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new version of a platelet-boosting medicine (romiplostim) for people whose platelets drop during cancer treatment. The goal is to see if it can safely raise platelet counts so you can continue your therapy.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests a drug called Romiplostim N01 to help platelet levels recover faster in people with blood cancers who have had a cord blood transplant. It may reduce the need for platelet transfusions and lower bleeding risk.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This study tests a new medication called romiplostim that may help raise your platelet count when it drops too low after radiation therapy. If you have a solid tumor and your platelets are below 75,000, this treatment could help you recover and avoid complications.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.